

Examining anxiety and depressive features in people with Parkinson's disease

Submission date 23/04/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 06/12/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 17/07/2024	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Approximately 40% of people with Parkinson's disease experience comorbid anxiety or depression, which are strong predictors of quality of life in Parkinson's. Little is known about how anxiety or depression develops in Parkinson's disease, and why some people with Parkinson's disease are more prone to anxiety than others. Anxiety and depression are associated with increased symptom burden; however, this is poorly understood at present. There is little evidence on effective treatments for anxiety in Parkinson's disease. The aim is to explore the aspects of emotional processing that are damaged in patients with Parkinson's disease and Anxiety.

Who can participate?

Patients at different stages of Parkinson's disease, ranging from early stages to advanced Parkinson's disease.

What does the study involve?

4 visits (screening, baseline, 6-month follow-up and 12-month follow-up. Participants will answer questions on their anxiety, and undergo assessment of movement, cognition, and computerised behavioural tasks, and an optional MRI scan.

What are the possible benefits and risks of participating?

None

Where is the study run from?

University College London (UK)

When is the study starting and how long is it expected to run for?

March 2021 to July 2024

Who is funding the study?

The research costs for the study have been supported by EU Commission grant (Horizon2020 grant 848002)

Who is the main contact?
Ms Saghi Arabi, s.arabi@ucl.ac.uk

Study website
<https://and-pd-ucl.netlify.app/>

Contact information

Type(s)
Scientific

Contact name
Ms Saghi Arabi

ORCID ID
<http://orcid.org/0000-0002-8029-7865>

Contact details
Room 2/690, Clinical Neurosciences Laboratories (Inst. of Neurology)
The Royal Free London NHS Foundation Trust
Rowland Hill St
London
United Kingdom
NW3 2PF
+44 (0)20 3108 5462
s.arabi@ucl.ac.uk

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
279691

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
CPMS 48056, Grant Codes: 848002, IRAS 279691

Study information

Scientific Title
Anxiety and depression in Parkinson's Disease

Acronym
AND-PD

Study objectives

The key objectives are to determine the risk factors and associated clinical features of anxiety and depression in Parkinson's Disease, and to identify the underlying biological changes associated with emotional dysfunction in Parkinson's Disease. The eventual aim will be to identify targets to design rational therapies for therapeutic trials to improve anxiety and depression in Parkinson's disease.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 12/03/2021, Yorkshire & The Humber - Bradford Leeds Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 104 8210; bradfordleeds.rec@hra.nhs.uk), REC ref: 21/YH/0016

Study design

Observational cross-sectional

Primary study design

Observational

Secondary study design

Cross sectional study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Anxiety and depression in Parkinson's Disease

Interventions

The study is an observational and longitudinal study. This design and methodology were chosen so that we could look at patients at different stages of Parkinson's disease; ranging from early stages to advanced Parkinson's disease. We will examine anxiety and depression in patients with PD, across disease stages, and subgroups. Healthy controls will be recruited to create an age-matched group.

The broad timetable for the stages of research are: preparation January 2020 - December 2020, assessments January 2021-December 2022, interpreting and analyzing data - 2023, preparing the final report, and disseminating results via conference presentations/peer-reviewed scientific journals (2024).

All assessments will take place either remotely online or at the Royal Free Hospital Campus, UCL or at King's College Hospital, London. Currently, there are no planned interim analyses or reports. To compensate for any possible research effects or biases, the analyses will be performed by a researcher blind to group (single-blind).

Visit 1:

Baseline assessment will occur after enrolment in the study. Participants with Parkinson's Disease will receive a combination of self-administered and/or researcher-administered scales to assess their clinical and cognitive symptoms online. Demographic data will be collected at baseline only. Assessments will take place either online or at one of the four NHS sites. Some questionnaires and assessments can be sent to the participant to be completed before the study day.

The optional MRI scans will be carried out at Wellcome Centre for Human Neuroimaging, Queen Square, London or at the Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroscience, London. The scans will be carried out by a radiographer and one of the researchers.

Visit 2 (last visit):

Participants with Parkinson's will receive a combination of self-administered and/or researcher-administered scales to complete, assessing their clinical and cognitive symptoms. This will take place online or when it is safe to do so, at one either Royal Free Hospital Campus, UCL or at King's College Hospital, London.

Intervention Type

Other

Primary outcome measure

Measured at baseline, 6 and 12 months:

1. Anxiety measured using the Parkinson Anxiety Scale (PAS)
2. Depression measured using the Patient Health Questionnaire (PHQ-9)

Secondary outcome measures

Measured at baseline, 6 and 12 months:

1. Anxiety and depression measured using a visual analogue scale of anxiety and mood
2. Non-motor symptoms measured using the MDS Non-Motor Rating Scale (MDS-NMS)
3. Non-motor and motor experiences of daily living and motor complications using the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
4. Activation in the ROIs measured using fMRI BOLD

Overall study start date

01/03/2021

Completion date

01/07/2024

Eligibility

Key inclusion criteria

1. Participants must be judged by the investigator to have capacity to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on

Harmonization (ICH), and local regulations. All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.

2. Willing and able to provide written consent

3. All participants must have adequate visual and auditory acuity according to investigator's judgement to complete the neuropsychological testing.

4. People with PD should have confirmed diagnosis of PD according to Movement Disorder Society Clinical Diagnostic Criteria and must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.

5. Aged 18 - 89 years

6. Can tolerate behavioural and psychological testing

7. Score of or above 14 on the PAS

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

89 Years

Sex

Both

Target number of participants

Planned Sample Size: 350; UK Sample Size: 350

Key exclusion criteria

General exclusion criteria

1. Past/present psychotic disorder, bipolar disorder/mania or alcohol/substance use disorder (outside a comorbid psychiatric episode) that would interfere in completing assessments or impair the safety of the participant.

2. History of medical illness that may impair cognitive function (e.g. serious head injury, endocrine disorder)

3. Atypical PD syndromes due to either drugs (e.g. metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g. Wilson's disease), encephalitis, or degenerative diseases (e.g. progressive supranuclear palsy).

4. Previously obtained MRI scan with evidence of clinically significant other neurological disorder (in the opinion of the Investigator).

MRI exclusion criteria

5. MRI contraindications such as a pacemaker, aneurysm clip, cochlear implant, neurostimulator, IUD, shrapnel, metal fragments in the eye, a weight of above 250lbs or claustrophobia.

6. There are no exclusionary medications for this study.

7. Females who are pregnant, planning pregnancy, or breastfeeding.

Date of first enrolment

01/07/2021

Date of final enrolment

30/06/2024

Locations

Countries of recruitment

England

United Kingdom

Wales

Study participating centre

Royal Free Hospital

Pond Street

London

United Kingdom

NW3 2QG

Study participating centre

University College Hospital

235 Euston Road

Fitzrovia

London

United Kingdom

NW1 2BU

Study participating centre

Luton & Dunstable University Hospital

Lewsey Rd

Luton

United Kingdom

LU4 0DZ

Study participating centre

King's College Hospital

Denmark Hill

London

United Kingdom

SE5 9RS

Study participating centre
NIHR Clinical Research Network North West
Mint Wing
St Mary's Hospital
Praed Street
London
United Kingdom
W2 1NY

Study participating centre
Royal United Hospital
Research and Development
Wolfson Centre, D1
Bath
United Kingdom
BA1 3NG

Study participating centre
Royal Cornwall Hospital
B21, The Knowledge Spa
Truro
United Kingdom
TR1 3HD

Study participating centre
Gwynedd Hospital
Ysbyty Gwynedd
Bangor
United Kingdom
LL57 2PW

Sponsor information

Organisation
University College London

Sponsor details
Joint Research Office, UCL
Gower Street
London

England
United Kingdom
WC1E 6BT
+44 203 447 5696
UCLH.randd@nhs.net

Sponsor type

University/education

Website

<http://www.ucl.ac.uk/>

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Government

Funder Name

European Commission

Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, Ευρωπαϊκή Επιτροπή, Европейская комиссия, Evropské komise, Commission européenne, Choimisiúin Eorpaigh, Europskoj komisiji, Commissione europea, La Commissione europea, Eiropas Komisiju, Europos Komisijos, Európai Bizottságrol, Europese Commissie, Komisja Europejska, Comissão Europeia, Comisia Europeană, Európskej komisii, Evropski komisiji, Euroopan komission, Europeiska kommissionen, EC, EU

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

31/12/2025

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No